Please assess the completion status of the following clinical trial:

Trial Title: A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy or for which standard therapy does not exist~* Patient has life expectancy of greater than 3 months~* Patient is able to swallow capsules~Exclusion Criteria:~* Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to taking study drug~* Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent~* Patient has active CNS metastases and/or carcinomatous meningitis~* Patient has primary central nervous system tumor~* Patient has a history of drug or alcohol abuse~* Patient has Hepatitis B or C~* Patient is HIV positive~* Patient has active infection or has received intravenous antibiotics, antiviral or antifungal agents 2 weeks before taking study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Arm A: Drug/Placebo
- B (Type: EXPERIMENTAL): Arm B: Placebo/Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).